Disgorging profits is a common and prominent feature these days in Foreign Corrupt Practices Act settlements with the Securities and Exchange Commission. Last year Siemens disgorged $350 million and this year KBR paid $177 million. Maybe because disgorgements now happen so often, or because the payments have become so enormous, we automatically accept them as […]
Search Results for: label/Titan – Page 2
Bob Beamon’s long jump of 29 feet 2½ inches in Mexico City in the 1968 Olympics broke the world record by an astounding 21¾ inches. With that one jump Beamon became the first man to reach both 28 and 29 feet, and the word Beamonesque was born — meaning a spectacular event. We’d describe Siemens’ […]
Marcelo Odebrecht (Image courtesy of the Economist via YouTube)Brazilian police arrested Marcelo Odebrecht, the billionaire CEO of the powerful Odebrecht conglomerate.
For those who missed any of the FCPA enforcement news during the recent hyper-active stretch, here’s what happened: July 28 — Label-maker Avery Dennison Corporation resolved civil and administrative charges brought by the Securities and Exchange Commission. The SEC filed settled enforcement actions in the United States District Court for the Central District of California […]
Label-maker Avery Dennison Corporation, whose compliance problems in China were described in an LA Times story last January, has resolved civil and administrative charges brought by the Securities and Exchange Commission. The SEC filed settled enforcement actions in the United States District Court for the Central District of California charging Avery with violating the FCPA’s […]
Following yesterday’s post, several readers suggested that we mention any other FCPA-related cases, appeals, sentencings and enforcement actions during the past year involving individuals. It’s a good idea, and our thanks go out to Marc and our other correspondents. _______________ Our post Kozeny’s Co-Defendant Wins Appeal (September 1, 2008) discusses Victor Kozeny, Frederic Bourke and […]
Shire Pharmaceuticals LLC will pay $56 million to settle allegations that its marketing and promotion of several drugs violated the False Claims Act, the Justice Department said Wednesday.